Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on March 10, 2023. The filing addresses a specific regulatory disclosure under Item 7.01 regarding the company's exposure to Silicon Valley Bank.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a specific event rather than a periodic financial report.
Material Changes
The filing confirms there are no material changes to the company's financial position related to Silicon Valley Bank. Specifically, the company reports:
- No exposure to Silicon Valley Bank.
- No cash deposits held with Silicon Valley Bank.
- No securities held with Silicon Valley Bank.
- No other business relationship with Silicon Valley Bank.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of general risks beyond the specific clarification regarding Silicon Valley Bank. The disclosure is intended to inform investors that the company is not affected by the banking sector events impacting Silicon Valley Bank.
Investor Verification Points
- Verify the company's cash holdings and banking relationships in subsequent quarterly reports (10-Q) or annual reports (10-K).
- Confirm the trading status of the common stock (DTIL) on The Nasdaq Global Select Market.
- Note that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.